



PATENTS
Attorney Docket No. ISA-035.01

1PW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Leong Loke Ng

Application No: 10/532,359

I.A. Filing Date: October 21, 2003

For: METHOD FOR PREDICTION OF
CARDIAC DISEASE


Art Unit: 3762

Confirmation No.: 1567

Examiner: Not yet known

CERTIFICATE OF MAILING/TRANSMISSION

I hereby certify that the correspondence is being sent via facsimile or deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 26, 2006.


John Barretto

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION-DISCLOSURE STATEMENT

UNDER CFR 1.97(b)(3)

Applicants hereby bring to the Examiner's attention the references listed on the accompanying form PTO-1449 in compliance with the requirement of 37 C.F.R. § § 1.56 and 1.97(b)(3). Pursuant to 37 C.F.R. § 1.98 (2)(i), Applicants have not enclosed copies of the cited U.S. patents or published applications. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.


Applicants have listed dates of publication on the attached PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any deficiencies or credit any overpayment to our **Deposit Account, No. 06-1448, Reference ISA-035.01.**

Respectfully submitted,

Date: April 26, 2006
Customer No: 25181
Patent Group
Foley Hoag, LLP
155 Seaport Blvd.
Boston, MA 02210-2600


Charlene A. Stern-Dombal, Reg. No. 57,961
Agent for Applicants
Tel. No. (617) 832-1738
Fax. No. (617) 832-7000



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/532359-Conf. #1567
				Filing Date	October 21, 2003
				First Named Inventor	Leong Ng
				Art Unit	3762
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	ISA-03501

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-5,290,678	03-01-1994	Jackowski	
	A2	US-5,560,368	10-01-1996	Berger	
	A3	US-5,604,105	02-18-1997	Jackowski	
	A4	US-5,682,901	11-04-1997	Kamen	
	A5	US-5,710,008	01-20-1998	Jackowski	
	A6	US-6,348,585	02-19-2002	Culp et al.	
	A7	US-6,534,322	03-18-2003	Sabbadini	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP 0 291 194	02-16-94			
	B2	EP 1 102 196	05-23-01			
	B3	EP 1 241 479	09-18-02			
	B4	WO 00/31265	06-02-00			
	B5	WO 00/35951	06-22-00			
	B6	WO 02/32932	04-25-02			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Ames et al., "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14", <i>Nature</i> , Vol. 401: pp. 282-286 (1999)		
	C2	Apple et al., "Preliminary Evaluation of the Vitros ECi Cardiac Troponin I Assay," <i>Clin Chem.</i> , 46(4):572-4 (2000)		
	C3	Bottrill et al., "Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries," <i>British Journal of Pharmacology</i> , Vol. 130, No. 8:1865-1870 (2000)		
	C4	Brenner et al., "Diverse Biological Actions of Atrial Natriuretic Peptide," <i>Physiological Reviews</i> , Vol. 70, No. 3:665-699 (1990)		
	C5	Collinson et al., "Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice," <i>Heart</i> , 89(3):280-6 (2003)		
	C6	Coulouarn et al., "Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord" <i>PNAS</i> , Vol. 95:15803-15808 (1998)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/532359-Conf. #1567
				Filing Date	October 21, 2003
				First Named Inventor	Leong Ng
				Art Unit	3762
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	ISA-03501

C7	Douglas <i>et al.</i> , "Human Urotensin-II is a Potent Vasoactive Peptide: Pharmacological Characterization in the Rat, Mouse, Dog and Primate," <i>Journal of Cardiovascular Pharmacology</i> , Vol. 36, Suppl. 1: S163-S166 (2000)	
C8	Douglas <i>et al.</i> , "Congestive heart failure and expression of myocardial urotensin II," <i>The Lancet</i> , Vol. 359:1990-1997 (2002)	
C9	Falahati <i>et al.</i> , "Implementation of serum cardiac troponin I as marker for detection of acute myocardial infarction," <i>Am Heart J.</i> , 137(2):332-7 (1999)	
C10	Hall, Christian, "The value of natriuretic peptides for the management of heart failure: current state of play," <i>European Journal of Heart Failure</i> , Vol. 3:395-397 (2001)	
C11	Hillier <i>et al.</i> , "Effects of Urotensin II in Human Arteries and Veins of Varying Caliber," <i>Circulation</i> , Vol. 103:1378-1381 (2001)	
C12	Houghton <i>et al.</i> , "Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography?," <i>Int. Journal of Cardiology</i> , 62:31-36 (1997)	
C13	Hughes <i>et al.</i> , "An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction," <i>Clinical Science</i> , Vol. 96:373-380 (1999)	
C14	James <i>et al.</i> , "N-terminal pro-brain natriuretic peptide and other risk marker the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a G Utilization of Strategies to Open occluded arteries (GUSTO-IV) substudy," <i>Circulation</i> , 108(3):275-81 (2003)	
C15	James <i>et al.</i> , "Troponin and C-Reactive Protein Have Different Relations to Subsequent Mortality and Myocardial Infarction After Acute Coronary Syndrome," <i>J Am Coll Cardiol.</i> , 41(6):916-24 (2003)	
C16	Karl <i>et al.</i> , "Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit," <i>Scand. J. Clin. Lab Invest.</i> , Vol. 59, Suppl. 230: 177-181 (1999)	
C17	Koller <i>et al.</i> , "Selective Activation of the B Natriuretic Peptide Receptor by C-Type Natriuretic Peptide (CNP)," <i>Science</i> , Vol. 252:120-123 (1991)	
C18	Lapp <i>et al.</i> , "Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy," <i>International Journal of Cardiology</i> 94, 94:93-97 (2004)	
C19	Le Moigne <i>et al.</i> , "Determination of myoglobin: comparative evaluation of the new automated VIDAS [®] assay with two other immunoassays," <i>Clin Biochem.</i> , 35:255-62 (2002)	
C20	Mair <i>et al.</i> , "A Decision Tree for the Early Diagnosis of Acute Myocardial Infarction in Nontraumatic Chest Pain Patients at Hospital Admission," <i>Chest</i> , Vol. 106, No. 6:1502-1509 (1995)	
C21	Mair <i>et al.</i> , "Rapid accurate diagnosis of acute myocardial infarction in patients with non-traumatic chest pain within 1 h of admission," <i>Coron Artery Dis</i> 1995, 6(7): 539-45 (1995)	
C22	Nielsen <i>et al.</i> , "Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests," <i>BMJ</i> , 320:220-224 (2000)	
C23	Ng <i>et al.</i> , "Non-competitive immunochemiluminometric assay for cardiotrophin-I detects elevated plasma levels in human heart failure," <i>Clinical Science</i> , 102: 411-416 (2002)	
C24	Ng <i>et al.</i> , "Plasma urotensin in human systolic heart failure," <i>Circulation</i> 2002, 106:2877-2880 (2002)	
C25	Ommand, <i>et al.</i> , "N-terminal pro-B-type natriuretic peptide and long arm mortality in acute coronary syndromes," <i>Circulation</i> , 106:2913-8 (2002)	
C26	Pearson <i>et al.</i> , "Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes," <i>PNAS</i> , 77(8):5021-5024 (1980)	
C27	Penttila <i>et al.</i> , "Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain," <i>Clin Biochem.</i> , 35:647-53 (2002)	
C28	Ribeiro <i>et al.</i> , "Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease," <i>The Lancet</i> , 360:461-462 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/532359-Conf. #1567
				Filing Date	October 21, 2003
				First Named Inventor	Leong Ng
				Art Unit	3762
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	ISA-03501

	C29	Richards, <i>et al.</i> , "B type natriuretic peptides and ejection fraction for prognosis after myocardial infarction," <i>Circulation</i> , 107:2786-92 (2003)	
	C30	Russell <i>et al.</i> , "Cardiostimulant effects of urotensin-II in human heart <i>in vitro</i> ," <i>British Journal of Pharmacology</i> , 132:5-9 (2001)	
	C31	Russell <i>et al.</i> , "Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure," <i>Am. J. Physiol. Heart Circ. Physiol.</i> 285:H1576-H1581 (2003)	
	C32	Stingo <i>et al.</i> , "Cardiovascular and renal actions of C-type natriuretic peptide," <i>The American Physiological Society</i> , H308-H312 (1992)	
	C33	Stingo <i>et al.</i> , "Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma" <i>The American Physiological Society</i> , H1318-H1321 (1992)	
	C34	Stirrat <i>et al.</i> , "Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries," <i>Am. J. Heart Circ. Physiol.</i> , Vol. 280:H925-H928 (2001)	
	C35	Suga <i>et al.</i> , "Endothelial Production of C-Type Natriuretic Peptide and Its Marked Augmentation by Transforming Growth Factor- β ," <i>J. Clin. Invest.</i> , 90:1145-1149 (1992)	
	C36	Tzanidis <i>et al.</i> , "Direct Actions of Urotensin II on the Heart Implications for Cardiac Fibrosis and Hypertrophy," <i>Circulation Research</i> , 93(3):246-253 (2003)	
	C37	Tzanidis <i>et al.</i> , "Urotensin-II stimulates collagen synthesis by cardiac fibroblasts in vitro: implications for myocardial remodelling," <i>ABSTRACT</i> (2000)	
	C38	Watanabe <i>et al.</i> , "Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation," <i>Journal of Hypertension</i> , 19(12):2191-2196 (2001)	
	C39	Zou <i>et al.</i> , "Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats," <i>Federation of European Biochemical Societies Letters</i> , 508:57-60 (2001)	
	C40	International Search Report dated January 29, 2004	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--